As a federal crackdown on Ozempic-style copycats looms, Hims is trying a unique new strategy to lobby lawmakers.

Emma Roma Jayne lost 130 pounds in two years, and says people treat her very differently.

Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain first-hand. Shares of the ...

Sen. Jim Banks (R-Ind.) wants the Food and Drug Administration to look into foreign-made active pharmaceutical ingredients he ...

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, ...

The average weight for women in the U.S. is 170.8 pounds, and the average height is 5 feet, 3 inches tall. These are mathematical calculations, so they don’t necessarily represent what’s typical or ...

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm ...

Minoxidil — a drug originally developed to treat high blood pressure — has been an effective treatment for hair loss in men ...

Learn how Stacker’s data-driven content strategy helps brands boost reach, build authority, and outperform benchmarks with ...

Citing third-party data, Hettenback said downloads of the Hims & Hers apps increased 47% year over year in February. What it means for Hims & Hers stock. On Apple's App Store, Him ...